# reload+after+2024-01-20 16:44:10.009713
address1§275 Wyman Street
address2§3rd Floor
city§Waltham
state§MA
zip§02451
country§United States
phone§617 945 5576
website§https://www.cogentbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
fullTimeEmployees§138
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Andrew R. Robbins M.B.A.', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 981403, 'exercisedValue': 0, 'unexercisedValue': 1230115}, {'maxAge': 1, 'name': 'Dr. John Edward Robinson Ph.D.', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 633726, 'exercisedValue': 0, 'unexercisedValue': 835001}, {'maxAge': 1, 'name': 'Dr. Jessica  Sachs M.D.', 'age': 48, 'title': 'Chief Medical Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 672502, 'exercisedValue': 0, 'unexercisedValue': 1742244}, {'maxAge': 1, 'name': 'Mr. John L. Green C.A., CPA', 'age': 43, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 763987, 'exercisedValue': 0, 'unexercisedValue': 266409}, {'maxAge': 1, 'name': 'Mr. Brad  Barnett', 'title': 'Chief Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Christi  Waarich', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Evan D. Kearns J.D.', 'age': 43, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erin  Schellhammer', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dana R. Martin Pharm.D.', 'title': 'Senior VP of Medical Affairs & Chief Patient Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Brad  Fell', 'title': 'VP & Head of Medicinal Chemistry', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.276
currency§USD
dateShortInterest§1702598400
forwardEps§-2.09
exchange§NMS
quoteType§EQUITY
shortName§Cogent Biosciences, Inc.
longName§Cogent Biosciences, Inc.
firstTradeDateEpochUtc§1522330200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3a4634b7-b227-3bef-b8b4-12fa6851bf14
gmtOffSetMilliseconds§-18000000
targetHighPrice§26.0
targetLowPrice§5.0
targetMeanPrice§15.67
targetMedianPrice§15.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§9
quickRatio§8.037
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
